SHPH Key Statistics, Chart & Performance
The current stock price of SHPH is 1.675 USD. In the past month the price decreased by -18.27%. In the past year, price decreased by -91.2%.
SHPH Technical Analysis
SHPH Financial Highlights
Over the last trailing twelve months SHPH reported a non-GAAP Earnings per Share(EPS) of -25.87. The EPS increased by 9.87% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -302.2% | ||
| ROE | -767.95% | ||
| Debt/Equity | 0.3 |
SHPH Forecast & Estimates
SHPH Ownership
SHPH Latest News, Press Relases and Analysis
SHPH Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.96 | 383.716B | ||
| AMGN | AMGEN INC | 16.26 | 197.191B | ||
| GILD | GILEAD SCIENCES INC | 16.71 | 181.425B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.91 | 119.38B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.6 | 81.459B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.36 | 46.497B | ||
| INSM | INSMED INC | N/A | 32.511B | ||
| NTRA | NATERA INC | N/A | 28.376B | ||
| BIIB | BIOGEN INC | 12.06 | 27.206B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.51 | 20.78B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About SHPH
Company Profile
Shuttle Pharmaceuticals Holdings, Inc. is a clinical stage pharmaceutical company, which engages in the development of novel therapies for cancer. The company is headquartered in Gaithersburg, Maryland and currently employs 9 full-time employees. The company went IPO on 2022-08-31. Its product candidates include Ropidoxuridine, a Phase II, clinical-stage radiation sensitizer, a platform of HDAC inhibitors (SP-1-161, SP-2-225 and SP-1-303), and two preclinical, prostate cancer-oriented diagnostics assets: PC-RAD Test, a blood test to predict clinical response to radiation therapy and PSMA-B ligand for potential use as a theranostic agent. Ropidoxuridine (IPdR) is for use in combination with RT to treat brain tumors (glioblastoma) and sarcomas. SP-1-161 is a candidate lead of compounds demonstrating activation of the ATM gene product (mutated in Ataxia-Telangiectasia). SP-2-225 is a candidate lead of compounds demonstrating Class II (HDAC6) selective inhibition. SP-1-303 is a candidate Class I HDAC inhibitor with preferential efficacy against ER positive cancers.
Company Info
SHUTTLE PHARMACEUTICALS HOLD
401 Professional Drive, Suite 260
Gaithersburg MARYLAND US
Employees: 9
Phone: 12404034212
SHUTTLE PHARMACEUTICALS HOLD / SHPH FAQ
What does SHUTTLE PHARMACEUTICALS HOLD do?
Shuttle Pharmaceuticals Holdings, Inc. is a clinical stage pharmaceutical company, which engages in the development of novel therapies for cancer. The company is headquartered in Gaithersburg, Maryland and currently employs 9 full-time employees. The company went IPO on 2022-08-31. Its product candidates include Ropidoxuridine, a Phase II, clinical-stage radiation sensitizer, a platform of HDAC inhibitors (SP-1-161, SP-2-225 and SP-1-303), and two preclinical, prostate cancer-oriented diagnostics assets: PC-RAD Test, a blood test to predict clinical response to radiation therapy and PSMA-B ligand for potential use as a theranostic agent. Ropidoxuridine (IPdR) is for use in combination with RT to treat brain tumors (glioblastoma) and sarcomas. SP-1-161 is a candidate lead of compounds demonstrating activation of the ATM gene product (mutated in Ataxia-Telangiectasia). SP-2-225 is a candidate lead of compounds demonstrating Class II (HDAC6) selective inhibition. SP-1-303 is a candidate Class I HDAC inhibitor with preferential efficacy against ER positive cancers.
What is the current price of SHPH stock?
The current stock price of SHPH is 1.675 USD. The price increased by 4.04% in the last trading session.
What is the dividend status of SHUTTLE PHARMACEUTICALS HOLD?
SHPH does not pay a dividend.
What is the ChartMill rating of SHUTTLE PHARMACEUTICALS HOLD stock?
SHPH has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Can you provide the sector and industry classification for SHUTTLE PHARMACEUTICALS HOLD?
SHUTTLE PHARMACEUTICALS HOLD (SHPH) operates in the Health Care sector and the Biotechnology industry.